BioMarin CEO replaces commercial chief—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to.
/PRNewswire/ ImmuneID - a biopharmaceutical company that uses existing antibody responses to rapidly unveil the complexities of the immune system, thereby.
Published: Apr 05, 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced that Annalisa D’Andrea, Ph.D., has been appointed President and Chief Scientific Officer. Dr. D’Andrea brings more than 25 years of experience in translational research in immunology to ImmuneID.
“The addition of Annalisa as President and CSO is an important milestone for ImmuneID, as the company applies its platform to identify promising immunological therapeutic targets,” said Stephen Elledge, Ph.D., ImmuneID co-founder and Chair of ImmuneID SAB, Lasker Award winner, and The Gregor Mendel Professor of Genetics and Medicine, Harvard Medical School. “Annalisa’s experience advancing drug candidates to the clinic will be extremely valuable and I look forward to working with her.”